1. Rubin MA, Girelli G, Demichelis F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol. 2016; 69(4) 4 These individuals are at increased risk of developing more severe Lyme disease sequelae, such as posttreatment Lyme disease syndrome, which was not discussed in the article. Drs Shapiro and Wormser also wrote that "There is a common misconception that poor sensitivity of antibody tests for Lyme disease is a major limitation." Two-tier testing of early Lyme disease patients at baseline is only 40% sensitive, and sensitivity increases to only 67.5% after treatment.
5 Poor diagnostic performance during early Lyme disease is problematic because more positive clinical outcomes are associated with earliest possible diagnosis and initiation of treatment. The authors went on to say, "However, this is a problem only if clinicians erroneously depend on serologic tests to make a diagnosis of Lyme disease in patients with erythema migrans, which typically precedes the development of detectable antibodies." Most patients do not recall a tick bite, 20% to 30% patients do not present with erythema migrans, 2 and not all rashes that appear to be erythema migrans are. 3 Thus, clinicians often must rely on an individual's case history combined with serological testing to make a timely and accurate differential diagnosis.
Scott Santarella, BA Timothy J. Sellati, PhD The numbers of cases of Lyme disease reported to the CDC, despite limitations in estimates, are a good way to monitor trends in incidence. They confirm our statement that there has not been a statistically significant increase in reported cases during the last 4 years. 4 There also is no significant difference in incidence of reported cases in the most recent 5-year period compared with the preceding 5-year period. 4 There has been a substantial increase in incidence over the past 20 to 30 years, but this has been a gradual, modest increase, with substantial year-to-year variation, rather than a sudden explosion of cases. Reactive serological test results from Quest Diagnostics are not a validated measure of the number of cases of Lyme disease that occur in the United States. There are numerous commercial laboratories. An increase in the number of positive results reported by a given laboratory may simply reflect a change in the number of tests performed rather than a true increase in incidence of disease. In addition, it is not clear whether 1 patient could be represented multiple times, and the results do not distinguish between a new-onset (incident) event and a positive result that could have been present for many years.
We did not suggest that persons with Lyme disease should not be treated. However, if the decision to treat a patient who has a skin lesion that might be erythema migrans is based solely on a positive serological test result, most patients with Lyme disease will not be treated or treatment will be delayed because the skin lesion typically develops before antibodies are detectable (ie, sensitivity is poor in early disease, but it is rarely required because the rash is very characteristic).
5 Conversely, to confirm Lyme disease as the cause of extracutaneous manifestations, a positive serological test result usually is needed. Almost all such patients will have positive serology (ie, sensitivity is excellent); however, a small proportion of patients with early neurological Lyme disease (<15%) will not have seropositivity until repeat testing is performed 1 to 2 weeks after initial presentation. In contrast, patients with late Lyme disease (eg, Lyme arthritis) will usually have seropositivity for IgG antibodies at the time of presentation. 5, 6 Seronegative late Lyme disease is not an established entity.
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